Sökning: onr:"swepub:oai:DiVA.org:kth-96444" >
Preclinical evaluat...
-
Altai, MohamedUppsala universitet,Enheten för biomedicinsk strålningsvetenskap,Vladimir Tolmachev
(författare)
Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with In-111 using a maleimido derivative of NODAGA
- Artikel/kapitelEngelska2012
Förlag, utgivningsår, omfång ...
-
Elsevier BV,2012
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:kth-96444
-
https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-96444URI
-
https://doi.org/10.1016/j.nucmedbio.2011.10.013DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-164424URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
QC 20120605
-
Introduction: Affibody molecules have demonstrated potential for radionuclide molecular imaging. The aim of this study was to synthesize and evaluate a maleimido derivative of the 1,4,7-triazacyclononane-l-glutaric acid-4,7-diacetic acid (NODAGA) for site-specific labeling of anti-HER2 Affibody molecule. Methods: The maleimidoethylmonoamide NODAGA (MMA-NODAGA) was synthesized and conjugated to Z(HER2:2395) Affibody molecule having a C-terminal cysteine. Labeling efficiency, binding specificity to and cell internalization by HER2-expressing cells of [In-111-MMA-NODAGA-Cys(61)]-Z(HER2:2395) were studied. Biodistribution of [In-111-MMA-NODAGA-Cys(61)]-Z(HER2:2395) and [In-111-MMA-DOTA-Cys(61)]-Z(HER2:2395) was compared in mice. Results: The affinity of [MMA-NODAGA-Cys(61)]-Z(HER2:2395) binding to HER2 was 67 pM. The In-1111-labeling yield was 99.6%+/- 0.5% after 30 min at 60 degrees C. [In-111-MMA-NODAGA-Cys(61)]-Z(HER2:2395) bound specifically to HER2-expressing cells in vitro and in vivo. Tumor uptake of [In-111-MMA-NODAGA-Cys(61)]-ZHER(2:2395) in mice bearing DU-145 xenografts (4.7%+/- 0.8% ID/g) was lower than uptake of [In-111-MMA-DOTA-Cys(61)]-Z(HER2:2395) (7.5%+/- 1.6% ID/g). However, tumor-to-organ ratios were higher for [In-111-MMA-NODAGA-Cys(61)]-Z(HER2:2395) due to higher clearance rate from normal tissues. Conclusions: MMA-NODAGA is a promising chelator for site-specific labeling of targeting proteins containing unpaired cysteine. Appreciable influence of chelators on targeting properties of Affibody molecules was demonstrated.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Perols, AnnaKTH,Molekylär Bioteknologi(Swepub:kth)u11lpgnl
(författare)
-
Eriksson Karlström, AmelieKTH,Molekylär Bioteknologi(Swepub:kth)u10x6l4n
(författare)
-
Sandström, MattiasUppsala universitet,Avdelningen för sjukhusfysik(Swepub:uu)masan637
(författare)
-
Boschetti, Frederic
(författare)
-
Orlova, AnnaUppsala universitet,Plattformen för preklinisk PET,Anna Orlova(Swepub:uu)annaorlo
(författare)
-
Tolmachev, VladimirUppsala universitet,Enheten för biomedicinsk strålningsvetenskap,Vladimir Tolmachev(Swepub:uu)vladtolm
(författare)
-
Uppsala universitetEnheten för biomedicinsk strålningsvetenskap
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Nuclear Medicine and Biology: Elsevier BV39:4, s. 518-5290969-80511872-9614
Internetlänk
Hitta via bibliotek
Till lärosätets databas